Join the BioNap Email List:

Research Coverage

Some recent articles from BioNap, Inc.

22nd Century Group (XXII)
Five Stocks That Should Get Acquired >> LINK (Sept 2016)
Quick Update following Q1 Results >> LINK (May 2016)
Licensing Deal with Celanese for CelFX filter >> LINK (May 2016)
Transcript of my Interview with the CEO >> LINK (April 2016)
All 15 SRNT Abstracts on SPECTRUM >> LINK (March 2016)
Update following Fourth Quarter 2015 results >> LINK (Feb 2016)
Article talking about FDA interest and the market opportunity for Brand-A >> LINK (Jan 2016)
Article summarizing clinical data for MTRP Application >> LINK (Jan 2016)
Initiation Article (Introduction to XXII)  >> LINK (Dec 2015)

Actinium Pharmaceuticals (ATNM)
JPM Meeting Notes >> LINK (January 2017)
What Does Seattle Genetic's Clinical Hold Mean For Actinium >> LINK (January 2017)
ASH Abstract Confirms positive view for Actimab-A >> LINK (November 2016)
Comparing Actimab-A to Seattle Genetics CD33A >> LINK (October 2016)
Generally Update on the story >> LINK (September 2016)
Actinium Initiates Phase 3 with Iomab-B >> LINK (June 2016)
Odds of success look good with for Phase 2 Actimab-A >> LINK (June 2016)
Phase 3 SIERRA with Iomab-B should unlock value in the shares >> LINK (April 2016)
How Celator's recent data in AML impacts Actinium >> LINK (March 2016)
Article looking at the CAR-T threat in AML >> LINK (Jan 2016)
Article highlighting Actimab-A data at ASH >> LINK (Dec 2015)
Initiation Article (Introduction to ATNM) >> LINK (Nov 2015)

BioSig Technologies, Inc. (BSGM)
Working towards PURE EP approval in 2017 >> LINK (November 2016)
Five Stocks That Should Get Acquired >> LINK (Sept 2016)
Mayo preclinical paper in JACC >> LINK (August 2016)
Partnership with Mayo Clinic >> LINK (July 2016)
What is BioSig Worth? >> LINK (June 2016)
Review of data at IDSS (BSGM vs. GE) >> LINK (May 2016)
Why Med Tech is outperforming Biotech >> LINK (April 2016)
Initiation Article (Introduction to BSGM)  >> LINK (March 2016)

BrainStorm Cell Therapeutics (BCLI)
Time To Go Long Brainstorm? >> LINK (January 2017)
Interview with Cheif of Neurology at MGH and ALS KOL >> LINK (November 2016)

BriaCell Therapeutics (BCTXF)
JPM Meeting Notes >> LINK (January 2017)
A look at Cancer Immunotherapy in 2017 >> LINK (January 2017)
Signs Point to progress at BriaCell >> LINK (September 2016)
BriaCell selects CRO to run Phase 1/2 study >> LINK (May 2016)
Poster with Biomarker analysis presented at AACR >> LINK (April 2016)
Company announced plans for Phase I/II Trial >> LINK (April 2016)
Article providing an update post face-to-face meeting with CEO >> LINK (Jan 2016)
Article highlighting an impressive case study from Phase 1 trial >> LINK (Nov 2015)
Initiation Article (Introduction to BCT)  >> LINK (Oct 2015)

CanFite Biopharma (CANF)
JPM Meeting Notes >> LINK (January 2017)
CF101 Update In Psoriasis >> LINK (November 2016)
CF102 Looks Like An Interesting NASH Play >> LINK (Sept 2016)
Can-Fite looks meaningfully undervalued >> LINK (August 2016)
Article on CF102 for Phase 2 hepatocellular carcinoma >> LINK (July 2016)
Can-Fite takes on Celgene's Otezla >> LINK (June 2016)
EMA clears protocol for Phase 3 CF101 RA Study >> LINK (June 2016)
Update on recent events >> LINK (April 2016)
Comprehensive update following Q4 Results >> LINK (Feb 2016)
Article comparing piclidenoson (CF101) to JAK inhibitors in RA >> LINK (Dec 2015)
Article on CF102 Preclinical NASH data >> LINK (Nov 2015)
Article on CF602 Preclinical for erectile dysfunction >> LINK (Oct 2015)

CoLucid Pharmaceuticals (CLCD)
Why After A Massive Run, CoLucid Still Looks Attractive >> LINK (October 2016)
CoLucid Facts About Migraine >> LINK (May 2016)

Exactus, Inc. (EXDI)
An Introduction to FibriLyzer >> LINK (Sept 2016)

HedgePath Pharma (HPPI)
JPM Meeting Notes >> LINK (January 2017)
Update on Phase 2b Data Looks Excellent >> LINK (October 2016)
My Valuation of HedgePath Pharma >> LINK (Sept 2016)
Analysis of Interim Phase 2b Data >> LINK (Aug 2016)
Introduction to HedgePath Pharma >> LINK (Aug 2016)

InVivo Therapeutics (NVIV)
JPM Meeting Notes >> LINK (January 2017)
Interview with CEO, Mark Perrin >> LINK (May 2016)
My valuation thoughts on InVivo >> LINK (April 2016)
Thoughts on the INSPIRE pivotal trial >> LINK (Jan 2016)
Article updating the situation >> LINK (Dec 2015)
Article on the current situation >> LINK (Aug 2015)

Immune Pharmaceuticals (IMNP)
JPM Meeting Notes >> LINK (January 2017)
Immune forms Pain & Neurology spin-off called Maxim >> LINK (Sept. 2016)
Further elucidation on the strategy with Ceplene >> LINK (June 2016)
Ceplene biomarker data presented at AACR >> LINK (April 2016)
Article providing an update on the company's oncology programs >> LINK (March 2016)
Follow-up to Bi-specific platform article >> LINK (Dec 2015)
Update on the immuno-oncology division >> LINK (Dec 2015)
Article highlighting the potential for a Nano-CsA >> LINK (Nov 2015)
Article on Bertilimumab Phase 2 for Ulcerative Colitis >> LINK (Oct 2015)
Article on Bertilimumab Phase 2 for Bullous Pemphigoid >> LINK (Sept 2015)

MabVax Therapeutics (MBVX)
JPM Meeting Notes >> LINK (January 2017)
Additional Phase 1 Data >> LINK (November 2016)
Five Stocks That Should Get Acquired >> LINK (Oct 2016)
Interim Phase 1 Data Looks Good >> LINK (Sept. 2016)
Introduction to the Story >> LINK (Sept. 2016)

Matinas Biopharma (MTNB)
JPM Meeting Notes >> LINK (January 2017)
MAT2501 Phase 1 Trial Initiation >> LINK (December 2016)
Phase 2 VVC Study Initiation >> LINK (Nov. 2016)
Introduction to the story >> LINK (Nov. 2016)

Oasmia Pharmaceuticals AB (OASM)
Positive OS Data In Ovarian Cancer >> LINK (May 2016)
Update on Recent Positive Events >> LINK (April 2016)
Initiation Article (Introduction to OASM)  >> LINK (March 2016)

Oryzon Genomics SA (ORY)
Phase 1 ORY-1001 data at ASH >> LINK (December 2016)
Update following Q3 Results >> LINK (October 2016)
Update following Q2 Results >> LINK (August 2016)
Update following Q1 Results >> LINK (May 2016)
Initiation Report (19-pages) >> LINK (Dec 2015)

Pieris Pharmaceuticals (PIRS)
A look at Cancer Immunotherapy in 2017 >> LINK (January 2017)
Five Stocks That Should Get Acquired >> LINK (Sept 2016)
Target validation on PRS-060 >> LINK (June 2016)

RedHill Biopharma (RDHL)
RHB-104 Final MS Data >> LINK (December 2016)
Update following Q3-2016 Results >> LINK (November 2016)
RHB-104 Phase just got more interesting >> LINK (October 2016)
Sum-Of-Parts Valuation of RedHill >> LINK (Sept 2016)
Article on Mesupron (Phase 2 for solid tumors) >> LINK (Aug 2016)
Article on the RHB-104 (Phase 3 for Crohn's Disease) >> LINK (July 2015)
Phase 1 Data On YELIVA for Solid Tumors >> LINK (June 2016)
Scientific and Potential Partnering review of YELIVA >> LINK (June 2016)
Interview with RDHL CEO, Dror Ben-Asher >> LINK (May 2016)
Article on RHB-105 (Phase 3 for H. pylori infection) Part-1 >> LINK (Feb 2016)
Article on Bekinda/RHB-102 (Phase 3 for acute gastroenteritis ) >> LINK (Nov 2015)

Relmada Therapeutics (RLMD)
What Cerecor's NMDA failure means for Relmada >> LINK (December 2016)
An Interview with Relmada Therapeutics >> LINK (October 2016)
Review of NMDA-receptor targeting for MDD >> LINK (July 2016)
Introduction to LevoCap-ER for pain >> LINK (June 2016)
Introduction to d-methadone for depression >> LINK (May 2016)

Revive Therapeutics (RVV.V)
21st Century Cures Act a big positive for Revive >> LINK (December 2016)
How Revive will close the Valuation Gap with Peers >> LINK (September 2016)
Revive Raises Cash to Move Forward >> LINK (August 2016)
Introduction to Bucillamine and Cystinuria >> LINK (June 2016)

Valeritas Holdings Inc. (VLRX)
JPM Meeting Notes >> LINK (January 2017)
Update following Q3 Results >> LINK (November 2016)
V-Go Saves Diabetics Money, Improves QoL >> LINK (October 2016)
Introduction to V-Go >> LINK (August 2016)

Vaxil Bio Ltd (VXL.V)
A look at Cancer Immunotherapy in 2017 >> LINK (January 2017)
Introduction to Vaxil and ImMucin neoantigen >> LINK (December 2016)

VistaGen Therapeutics (VTGN)
JPM Meeting Notes >> LINK (January 2017)
Stem Cell deal with BlueRock >> LINK (December 2016)
What Cerecor's NMDA failure means for VistaGen >> LINK (December 2016)
Does AV101 Have Abilify-like Potential >> LINK (October 2016)
Five Stocks That Should Get Acquired >> LINK (October 2016)
Is VistaGen the Next Big Winner in CNS >> LINK (September 2016)
Interview with CMO Dr. Mark Smith >> LINK (Aug 2016)
Review of NMDA-receptor targeting for MDD >> LINK (July 2016)
AV-101 is a Blockbuster for Major Depression >> LINK (June 2016)

Vitality Biopharma (VBIO)
JPM Meeting Notes >> LINK (January 2017)
Cure Act Should Benefit Cannabis Industry >> LINK (December 2016)
Taking cannabinoid research to the next level >> LINK (November 2016)

No comments:

Post a Comment